Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.38 |
| ▸ | FCER2 | P06734 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.36 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.36 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.36 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.36 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.36 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.36 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.36 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392611 | 0.76 | MME (0.45) | AGTR1MMEHDAC3HDAC4HDAC1 | |
| SCHEMBL9552360 | 0.71 | AGTR1 (0.54) | AGTR1PPARG | |
| SCHEMBL2392191 | 0.71 | AGTR1 (0.48) | AGTR1PPARGMME | |
| SCHEMBL7335790 | 0.68 | AGTR1 (0.42) | AGTR1PPARG | |
| SCHEMBL9552782 | 0.68 | AGTR1 (0.52) | AGTR1PPARG | |
| SCHEMBL9552229 | 0.67 | AGTR1 (0.52) | AGTR1PPARG | |
| SCHEMBL9554033 | 0.67 | AGTR1 (0.52) | AGTR1PPARG | |
| SCHEMBL9552312 | 0.66 | AGTR1 (0.56) | AGTR1PPARG | |
| SCHEMBL9552051 | 0.66 | AGTR1 (0.52) | AGTR1PPARG | |
| SCHEMBL11622266 | 0.66 | ANPEP (0.59) | HDAC3HDAC4HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865755-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8338418-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120214849-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8080572-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110230525-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7863309-B2 | imidazole or triazole derivatives such as 4-[4-((R)-1-Benzyl-2-hydroxycarbamoylethylcarbamoyl)-2-butylimidazol-1-ylmethyl]benzoic acid methyl ester, used for treating congestive heart failure or as hypotensive agents | THERAVANCE, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100022599-A1 | imidazole or triazole derivatives such as 4-[4-((R)-1-Benzyl-2-hydroxycarbamoylethylcarbamoyl)-2-butylimidazol-1-ylmethyl]benzoic acid methyl ester, used for treating congestive heart failure or as hypotensive agents | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885PPARG 2988/4885MME 6/4885 |
| US-20110230525-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885PPARG 2988/4885MME 6/4885 |
| US-20100022599-A1 | imidazole or triazole derivatives such as 4-[4-((R)-1-Benzyl-2-hydroxycarbamoylethylcarbamoyl)-2-butylimidazol-1-ylmethyl]benzoic acid methyl ester, used for treating congestive heart failure or as hypotensive agents | AGTR1, REN, AGTR2 | AGTR1 1/4885PPARG 1596/4885MME 4/4885 |
| US-20120214849-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885PPARG 2988/4885MME 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.